Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on November 7, 2022, covering events occurring on November 4, 2022. The filing details a corporate restructuring involving the exchange of common stock for newly designated Series A convertible preferred stock.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on capital structure changes.
Material Changes
- Stock Exchange: On November 4, 2022, the Company entered an Exchange Agreement with specific stockholders (Biotechnology Value Fund entities and MSI BVF SPV, LLC).
- Transaction Details: Stockholders exchanged 10,000,000 shares of Common Stock for 1,000,000 shares of newly designated Series A Convertible Preferred Stock.
- Capital Structure Impact: Upon completion (anticipated November 9, 2022), the Company will have 200,090,850 shares of Common Stock outstanding and 1,000,000 shares of Preferred Stock outstanding.
- Preferred Stock Terms:
- Conversion: Each Preferred share converts into 10 Common shares at the holder's option.
- Conversion Blocker: Conversion is prohibited if the holder's beneficial ownership exceeds 9.99% of total Common Stock (initially), extendable to 19.99% with 60 days' notice.
- Voting Rights: Generally no voting rights, except as required by law or to amend Preferred Stock terms.
- Liquidation: Participates pari passu with Common Stock.
- Dividends: Entitled to equivalent dividends on an as-converted basis if declared on Common Stock; otherwise no dividends.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The transaction was executed under Section 3(a)(9) of the Securities Act of 1933 as an unregistered sale of equity securities.
Investor Verification Checklist
- Verify the final completion date of the Exchange (anticipated November 9, 2022).
- Confirm the updated total share count of Common Stock and Preferred Stock post-exchange.
- Review the full text of the Exchange Agreement (Exhibit 10.1) for specific limitations on conversion.
- Examine the Certificate of Designation (Exhibit 3.1) for complete rights and preferences of the Series A Preferred Stock.
- Monitor future filings for any changes to the Conversion Blocker percentage.